{"filing":{"accession_number":"0001193125-26-326309","cik":"0001796280","ticker":"ORIC","company_name":"Oric Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-28","primary_document":"d169933d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1796280/000119312526326309/d169933d8k.htm"},"events":[{"id":22264,"run_id":20129,"accession_number":"0001193125-26-326309","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board approved an amendment to the Inducement Equity Incentive Plan increasing reserved shares from 2,250,000 to 3,350,000 (an additional 1,100,000 shares) effective July 28, 2026. This is a compensatory arrangement disclosure under Item 5.02(e), involving equity awards and plan amendments that would materially affect the registrant's capital structure and executive compensation capacity. The filing explicitly describes the plan's purpose to grant equity-based awards to employees and non-employee directors as inducement compensation.","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22156,"accession_number":"0001193125-26-326309","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Board approved an amendment to the Inducement Equity Incentive Plan increasing reserved shares from 2,250,000 to 3,350,000 (an additional 1,100,000 shares) effective July 28, 2026. This is a compensatory arrangement disclosure under Item 5.02(e), involving equity awards and plan amendments that would materially affect the registrant's capital structure and executive compensation capacity. The filing explicitly describes the plan's purpose to grant equity-based awards to employees and non-employee directors as inducement compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:23:53.678816+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22156,"accession_number":"0001193125-26-326309","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Board approved an amendment to the Inducement Equity Incentive Plan increasing reserved shares from 2,250,000 to 3,350,000 (an additional 1,100,000 shares) effective July 28, 2026. This is a compensatory arrangement disclosure under Item 5.02(e), involving equity awards and plan amendments that would materially affect the registrant's capital structure and executive compensation capacity. The filing explicitly describes the plan's purpose to grant equity-based awards to employees and non-employee directors as inducement compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-31T00:23:53.678816+00:00","company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","filing_date":"2026-07-30"}]}